SPA
ANIP icon

Sherbrooke Park Advisers’s ANI Pharmaceuticals ANIP Stock Holding History

Sherbrooke Park Advisers’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,911
Closed -$358K – 201
2025
Q3 		$358K Buy
+3,911
New +$319K 0.17% 245
2024
Q3 		– Sell
-5,280
Closed -$336K – 895
2024
Q2 		$336K Buy
+5,280
New +$343K 0.06% 574

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.66B AUM 27.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sherbrooke Park Advisers's ANIP Position: Q4 2025 in Review

Sherbrooke Park Advisers sold out of ANI Pharmaceuticals (ANIP) in Q4 2025, closing a stake of 3,911 shares — an estimated $358K sold.

Sherbrooke Park Advisers first reported a position in ANIP in Q2 2024 and held it in 2 quarters. The position peaked at $358K in Q3 2025. 284 funds tracked by Wall St. Rank hold ANIP as of Q4 2025.

  • Sherbrooke Park Advisers reported no remaining ANI Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 3,911 ANI Pharmaceuticals shares in Q4 2025, an estimated $358K.
  • Sherbrooke Park Advisers first reported a position in ANI Pharmaceuticals in Q2 2024 and held it in 2 quarters.
  • Sherbrooke Park Advisers's ANI Pharmaceuticals position peaked at $358K in Q3 2025.
  • 284 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q4 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.